Total nucleated cell dose in graft is a better prognostic factor for survival in pediatric patients transplanted with bone marrow compared to CD34+, CD3+, or total mononuclear cell count.
Serhan KupeliGul InanAyse OzkanGulay SezginIbrahim BayramAtila TanyeliPublished in: Journal of clinical apheresis (2021)
Our data suggest that TNC dose is a better prognostic factor for pediatric allogeneic HSCT outcomes than doses of CD34+ cells, CD3+ cells, or TMC in patients transplanted with bone marrow. Future studies analyzing cell subsets and other components in TNC could elaborate the factor(s) accompanying this observed survival advantage.
Keyphrases
- prognostic factors
- bone marrow
- single cell
- induced apoptosis
- cell therapy
- mesenchymal stem cells
- end stage renal disease
- peripheral blood
- ejection fraction
- stem cells
- chronic kidney disease
- young adults
- electronic health record
- patient reported outcomes
- type diabetes
- oxidative stress
- hematopoietic stem cell
- peritoneal dialysis
- artificial intelligence